Table 3. Baseline characteristics for patients with different prognoses.
| Characteristics | Unfavorable | Favorable | P-value |
|---|---|---|---|
| n = 176 | n = 487 | ||
| Age, mean (SD) | 71.59 (11.87) | 65.08 (12.39) | 0.899 |
| Male, n (%) | 109 (61.9) | 342 (70.2) | 0.043 |
| Hypertension, n (%) | 142 (80.7) | 373 (76.6) | 0.264 |
| Diabetes, n (%) | 86 (48.9) | 176 (36.1) | 0.003 |
| Dyslipidemia, n (%) | 5 (2.8) | 29 (6.0) | 0.108 |
| Coronary heart disease, n (%) | 36 (20.5) | 51 (10.5) | 0.001 |
| AF, n (%) | 29 (16.5) | 27 (5.5) | <0.001 |
| NIHSS, median (IQR) | 6 (4–11) | 3 (1–4) | <0.001 |
| WBC, median (IQR) | 7.23 (6.2–8.5) | 6.60 (5.5–7.8) | <0.001 |
| Neutrophil, median (IQR) | 5.12 (3.9–6.3) | 4.20 (3.3–5.2) | <0.001 |
| Lymphocyte, median (IQR) | 1.40 (1.0–1.8) | 1.60 (1.3–2.1) | <0.001 |
| NLR, median (IQR) | 3.47 (2.5–5.7) | 2.57 (1.9–3.5) | <0.001 |
| PLR, median (IQR) | 125.42 (94.5–190.3) | 110.91 (87.5–145.6) | <0.001 |
| PNR, median (IQR) | 37.13 (27.81–48.49) | 43.25 (34.41–54.81) | <0.001 |
| PWR, median (IQR) | 25.56 (19.50–41.64) | 27.17 (22.22–33.33) | 0.002 |
| OCSP classification | <0.001 | ||
| TACI | 14 (8.0) | 12 (2.5) | |
| PACI | 66 (37.5) | 180 (37.0) | |
| POCI | 71 (40.3) | 183 (37.6) | |
| LACI | 25 (14.2) | 112 (223.0) | |
| Treatment after admission | |||
| Antiplatelet | 164 (93.2) | 467 (95.9) | 0.150 |
| Anticoagulation | 93 (52.8) | 188 (38.6) | 0.001 |
| Thrombolysis | 6 (3.4) | 14 (2.9) | 0.722 |
| Lipid-lowering | 167 (94.9) | 479 (98.4) | 0.022 |
Abbreviations: AF, Atrial Fibrillation; NIHSS, National Institutes of Health Stroke Scale; WBC, White Blood Cell; NLR, Neutrophil-to-Lymphocyte Ratio; PLR, Platelet-to-Lymphocyte Ratio; PNR, Platelet-to-Neutrophil Ratio; PWR, Platelet-to-White Blood Cell Ratio; OCSP, Oxfordshire Community Stroke Project; TACI, Total Anterior Cerebral Infarction; PACI, Partial Anterior Cerebral Infarction; POCI, Posterior Cerebral Infarction; LACI, Lacunar Cerebral Infarction.